Drybench Patent.
ISAVUCONAZONIUM SULFATE, NDA 207501
The patents and exclusivities FDA's Orange Book lists for NDA 207501 as captured on 14 October 2026, each date named by its rule and its rows, and the rows of FDA's Paragraph IV list that give this NDA's number, as captured on 17 October 2026. Listed protection is a range of dates, never one date.
FDA capture · review pending. Each row is shown as captured from FDA's Orange Book files and Paragraph IV list. Dates are FDA's own; spreadsheet day numbers are shown as dates, and a cell that cannot be read as one date is shown as written and left out of the range. Where FDA lists a *PED row without flags, its flags are read from the base row and marked so. A Paragraph IV row is placed here only by the number in its RLD/NDA cell; nothing is joined by name. How this page reads FDA's files has not been independently reviewed by a regulatory-affairs reviewer.
- Orange Book captured
- 14 October 2026
- Paragraph IV list captured
- 17 October 2026
- Last checked
- 30 October 2026
- Data-branch commit
- dadcab56563716abea6c5e31a5e1970080c778ef
Listed protection is a range of the dates FDA lists, not a forecast of market entry, and not legal, regulatory or investment advice.
Dates as listed in FDA's Orange Book capture of 14 October 2026. This page does not say whether a date has passed; compare it with today's date and FDA's current Orange Book. This page shows only what the capture of 14 October 2026 lists. It does not show patents or exclusivities listed before and since removed.
Listed protection
Listed dates run from 6 Mar 2022 to 8 Jun 2031, each by its own rule; no one date stands for this product.
- Earliest listed date
- 6 Mar 2022ODE-305 exclusivityRule R3 · Product 001 · exclusivity.txt line 614
- Latest listed date
- 8 Jun 2031PED exclusivityRule R3 · Product 001 · exclusivity.txt lines 619–620
- Latest substance patent
- 30 Apr 2026US 6,812,238 with pediatric exclusivity, as listedRule R2 · Product 001 · patent.txt line 7,272
- Latest listed patent
- 30 Apr 2026US 6,812,238 with pediatric exclusivity, as listedRule R2 · Product 001 · patent.txt line 7,272
- Latest exclusivity
- 8 Jun 2031PED exclusivityRule R3 · Product 001 · exclusivity.txt lines 619–620
Products
Each product number FDA lists under NDA 207501, as listed. The sections below name products by these numbers.
Product 001 · CRESEMBA
- Dosage form; route
- POWDER;INTRAVENOUS
- Strength
- 372MG
- Approval date as listed
- 6 Mar 2015
- Type as listed
- RX
- Applicant as listed
- ASTELLAS PHARMA US INC
Listed patents
Every patent the FDA lists for this product, as the application holder submitted it, with its flags. The FDA does not verify listings.
2 entries from 2 rows as listed; rows merge only where every cell shown is the same, each with its product numbers.
US 6,812,238, substance patent
patent.txt line 7,273- Expiry as listed
- 31 Oct 2025
- Rule
- R1
- Flags
- substance
- Product numbers
- 001
US 6,812,238 with pediatric exclusivity, as listed
patent.txt line 7,272- Expiry as listed
- 30 Apr 2026
- Rule
- R2
- Flags
- substance · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001
Listed exclusivities
Each exclusivity FDA lists for NDA 207501, with its code, FDA's definition of the code where the store's code list gives one, and its date as listed.
ODE-305 exclusivity
exclusivity.txt line 614- Date
- 6 Mar 2022
- Rule
- R3
- Definition
- Orphan drug exclusivity (to be checked against FDA's list)
- Product numbers
- 001
ODE-90 exclusivity
exclusivity.txt line 617- Date
- 6 Mar 2022
- Rule
- R3
- Definition
- Orphan drug exclusivity (to be checked against FDA's list)
- Product numbers
- 001
PED exclusivity
exclusivity.txt lines 621–622- Date
- 6 Sep 2022
- Rule
- R3
- Definition
- Pediatric exclusivity (to be checked against FDA's list)
- Product numbers
- 001
NPP exclusivity
exclusivity.txt line 613- Date
- 8 Dec 2026
- Rule
- R3
- Definition
- New patient population (to be checked against FDA's list)
- Product numbers
- 001
PED exclusivity
exclusivity.txt line 618- Date
- 8 Jun 2027
- Rule
- R3
- Definition
- Pediatric exclusivity (to be checked against FDA's list)
- Product numbers
- 001
GAIN exclusivity
exclusivity.txt lines 611–612- Date
- 6 Sep 2027
- Rule
- R3
- Definition
- Generating Antibiotic Incentives Now (to be checked against FDA's list)
- Product numbers
- 001
ODE-453 exclusivity
exclusivity.txt line 615- Date
- 8 Dec 2030
- Rule
- R3
- Definition
- Orphan drug exclusivity (to be checked against FDA's list)
- Product numbers
- 001
ODE-459 exclusivity
exclusivity.txt line 616- Date
- 8 Dec 2030
- Rule
- R3
- Definition
- Orphan drug exclusivity (to be checked against FDA's list)
- Product numbers
- 001
PED exclusivity
exclusivity.txt lines 619–620- Date
- 8 Jun 2031
- Rule
- R3
- Definition
- Pediatric exclusivity (to be checked against FDA's list)
- Product numbers
- 001
Paragraph IV list rows giving NDA 207501
The rows of FDA's Paragraph IV certifications list as captured on 17 October 2026 whose RLD/NDA cell gives NDA 207501, each cell as listed.
FDA's Paragraph IV list names no patent number, so it does not say which of the patents on this page an applicant certified against.
The list gives the last qualifying patent's expiry without pediatric exclusivity; in the app's Patents view, the Orange Book lists any *PED period as a separate row with its own date. The two dates describe different things. A blank cell is one FDA left blank in its list. Dates are FDA's own; the last qualifying patent expiry is not recomputed from the Orange Book.
Rows whose RLD/NDA cell we could not read as exactly one NDA number are kept apart on the list page; some may concern this product.
Rows on FDA's Paragraph IV list whose RLD/NDA cell gives NDA 207501
Isavuconazonium Sulfate · For Injection · 372 mg/vial
RLD/NDA as listed: Cresemba 207501- First PIV submission
- 6 Sep 2024
- ANDAs
- 2
- 180-day status
- Extinguished
- Decision posted
- 5 Jan 2026
- First applicant approval
- blank
- First marketing
- blank
- Last qualifying patent expiry (as listed by FDA)
- 31 Oct 2025
Notes from the trace
- R6 tentative approvals: not in the Orange Book data files as captured; the Drugs@FDA join is a later ruling.
Patents vs FDA exclusivityHow to read the Orange Book data filesParagraph IV certificationWhat changed, by week